clinical endpoint is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-27. Numbers and descriptions here follow the published literature rather than marketing material.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Genes for human growth hormone, known as growth hormone 1 (somatotropin; pituitary growth hormone) and growth hormone 2 (placental growth hormone; growth hormone variant), are localized in the q22-24 region of chromosome 17 and are closely related to human chorionic somatomammotropin (also known as placental lactogen) genes. GH, human chorionic somatomammotropin, and prolactin belong to a group of homologous hormones with growth-promoting and lactogenic activity.
Meanwhile, tensions with Mexico remain at a critical point; although President Claudia Sheinbaum has rejected unilateral military intervention, the threatened use of drones and precision strikes against fentanyl laboratories in border regions has become a recurring tool of the current administration in its effort to curb the opioid crisis. On March 6, 2026 the United States directly participated in the Ecuadorian conflict against drug traffickers as part of a joint Ecuadorian Operation on the border of Colombia dubbed Operation "Total Extermination" against the Comandos de la Frontera, a group of FARC dissidents believed to be drug smuggling. It was not clear how many were killed or captured, but it has been indicated that the Comandos camp had a capacity of 50 people according to Ecuador's defense ministry. This marks the first instance of a direct military participation by the United States in the Ecuadorian conflict. During the second presidency of Donald Trump, the CIA will play a larger and more aggressive role in combating drug cartels. It has been reported that the CIA has been conducting covert surveillance operations with unarmed drones in Mexico to monitor cartel activities.
== Adenlylylation in Eukaryotes == Plants and yeasts have no known endogenous AMPylating enzymes, but animal genomes are endowed with a single copy of a gene encoding a Fic-domain AMPylase, that was likely acquired by an early ancestor of animals via horizontal gene transfer from a prokaryote. The human protein referred to commonly as FICD, had been previously identified as Huntingtin associated protein E (HypE; an assignment arising from a yeast two-hybrid screen, but of questionable relevance, as Huntingtin and HypE/FICD are localised to different cellular compartments). CG9523 Homologues in Drosophila melanogaster (CG9523) and C. elegans (Fic-1) have also received attention. In all animals FICD has a similar structure. It is a type II transmembrane domain protein, with a short cytoplasmic domain followed by membrane anchor that holds the protein in the endoplasmic reticulum (ER) and long C-terminal portion that resides in ER and encompasses tetratricopeptide repeats (TPRs) followed by a catalytic Fic domain.
Sources: en.wikipedia.org
Richards echoed this sentiment, writing in a 2007 review, "[psychedelic] mushroom use may constitute one technology for evoking revelatory experiences that are similar, if not identical, to those that occur through so-called spontaneous alterations of brain chemistry." A group of researchers from Johns Hopkins School of Medicine led by Roland Griffiths conducted a study to assess the immediate and long-term psychological effects of the psilocybin experience, using a modified version of the mystical experience questionnaire and a rigorous double-blind procedure. When asked in an interview about the similarity of his work to Leary's, Griffiths explained the difference: "We are conducting rigorous, systematic research with psilocybin under carefully monitored conditions, a route which Dr. Leary abandoned in the early 1960s." Experts have praised the National Institute of Drug Abuse-funded study, published in 2006, for the soundness of its experimental design. In the experiment, 36 volunteers with no experience with hallucinogens were given psilocybin and methylphenidate (Ritalin) in separate sessions; the methylphenidate sessions served as a control and psychoactive placebo. The degree of mystical experience was measured using a questionnaire developed by Ralph W. Hood; 61% of subjects reported a "complete mystical experience" after their psilocybin session, while only 13% reported such an outcome after their experience with methylphenidate.
=== Manufacturing and processing of plastic === PVC and plastic production produces PVC dust. Increased hepatobiliary (liver, bile duct, and gallbladder) cancer mortality has been documented among vinyl and PVC workers exposed to vinyl chloride, the monomer from which PVC is made. Coronary artery disease and cancer death has been documented among workers exposed to vinyl chloride. 3D printing, such as commercial extrusion printing and multi-jet fusion printing with thermoplastics and resin, emits MNPs and volatile organic compounds into the ambient workplace air. There is emerging evidence of allergic, respiratory, and cardiovascular adverse effects from 3D printing. For extrusion printing, Acrylonitrile butadiene styrene (ABS) filaments emit more MNPs than Polylactic acid (PLA) filaments. Dust generation occurs in a wide range of settings from composite material machining, drilling, hand-held grinding, sanding of nanotube-containing composites, sanding of dental composites, and cutting PVC piping and plastics.
=== Dressings === It is not certain which dressings and topical agents are most effective for healing venous leg ulcers. Silver-containing dressings may increase the probability of healing for venous leg ulcers. A 2013 Cochrane systematic review aimed to determine the effectiveness of foam dressings for helping to heal venous leg ulcers. The authors concluded that it is uncertain whether or not foam dressings are more effective than other dressing types and that more randomized controlled trials are needed to help answer this research question. However, there is some evidence that ibuprofen dressings may offer pain relief to people with venous leg ulcers.
In 1992, the owner of all Tim Hortons and Wendy's restaurants in Prince Edward Island, Daniel P. Murphy, decided to open new franchise outlets for both brands in the same building in the town of Montague. Murphy invited Joyce and Wendy's chairman Dave Thomas to the grand opening of the "combo store," where the two executives met for the first time. Murphy's success with combining coffee and donuts with Wendy's fast food led to the August 8, 1995, acquisition of and merger with TDL Group by Wendy's International, Inc., an American company; this lasted until 2009. The sale was widely commented on in the media. In 1995, the Toronto Star had a column reflecting on Tim Hortons "selling out" to Wendy's with "the spectacle of another great Canadian icon...gone to Yankee burgerfat".
Sources: en.wikipedia.org
=== Human === In early studies, cultured human HL-60 promyelocytes purposely differentiated to granulocytes were used to partially purify and in a series of experiments clone FPR1; an apparent homolog of FPR1, Fpr was also cloned from rabbit neutrophils. The studies indicated that FPR1 is a G protein-coupled receptor that activates cells though a linkage to the pertussis toxin-sensitive Gαi subclass of G proteins, that FPR1 is located on chromosome 19q.13.3, and that this gene consists of two exons, the first of which encodes a 66 base pair 5'-untranslated sequence, the second of which has an intronless open reading frame coding for a protein containing ~354 amino acids; the studies also indicated that cells express multiple formyl peptide receptor mRNA transcripts due to Allelic heterogeneity, alternate Polyadenylation sites, and possibly products of other genes with homology to FPR1. Subsequent studies cloned two other genes with homology to FPR1 viz., FPL2 (originally termed FPR1, FPRH1, or FPRL1) and FPR3 (originally termed FPR2, FPRH2, or FPRL2). FPR2 and FPR3 are composed of 351 and 352 amino acids, respectively, and similar to FPR1 have intronless open reading frames which encode G protein coupled receptors; FPR2 and FPR3 have 66% and 56% amino acid sequence identity with FPR1 and 72% homology to each other.
The circulatory system is a system of organs that includes the heart, blood vessels, and blood which is circulated throughout the body. It includes the cardiovascular system, which consists of the heart and blood vessels. Some sources use the terms cardiovascular system, vascular system and circulatory system interchangeably. The lymphatic system (comprising lymphatic vessels, lymph nodes, lymphoid organs, lymphatic tissue and lymph) is complementary to the circulatory system and forms part of the immune system.
Arsenal financed moves for Granit Xhaka and Shkodran Mustafi in mid-2016 for a combined £65 million, rendering the pair one of Arsenal's most expensive ever signings, as Wenger hoped to guide the club to their first league title win in over thirteen years the following season. Although Arsenal began strongly in the league, losing only once until December, back-to-back defeats to Everton and Manchester City resulted in Arsenal losing their stronghold on the league. Wenger also served a four-match touchline ban and had to pay a £25,000 fine after pushing referee Anthony Taylor during a win at home against Burnley. Further defeats to Chelsea and Liverpool all but rendered Arsenal out of the title race, and left qualification to the Champions League threatened by March. On 30 April, Arsenal lost to main rivals Tottenham which had confirmed the latter had finished above them in the Premier League for the first time since the 1994–95 FA Premier League season. The following month also saw them fail to finish in the top four since the 1996–97 FA Premier League season. On 27 May, Wenger became the most successful manager in the history of the FA Cup as Arsenal beat Premier League winners Chelsea 2–1 at Wembley through goals from Alexis Sánchez and Aaron Ramsey. The victory represented a further record for Wenger, as Arsenal too, became the most successful club in the competition's history as they won the competition for the 13th time. Four days following the win, Wenger signed a contract extension until 2019.
John Barry Larson (born July 22, 1948) is an American politician and businessman who has been serving as the U.S. representative for Connecticut's 1st congressional district since 1999. The district is based in the state capital, Hartford. A member of the Democratic Party, Larson chaired the House Democratic Caucus during the 111th and 112th United States Congress. Larson was first elected to Congress in 1998, serving fourteen consecutive terms in the House. He attempted to seek a fifteenth term, but he was defeated in the 2026 Democratic primary by former Hartford mayor Luke Bronin.
== Function == Flavoproteins utilize the unique and versatile structure of flavin moieties to catalyze difficult redox reactions. Since flavins have multiple redox states they can participate in processes that involve the transfer of either one or two electrons, hydrogen atoms, or hydronium ions. The N5 and C4a of the fully oxidized flavin ring are also susceptible to nucleophilic attack. This wide variety of ionization and modification of the flavin moiety can be attributed to the isoalloxazine ring system and the ability of flavoproteins to drastically perturb the kinetic parameters of flavins upon binding, including flavin adenine dinucleotide (FAD). The number of flavin-dependent protein encoded genes in the genome (the flavoproteome) is species dependent and can range from 0.1% - 3.5%, with humans having 90 flavoprotein encoded genes. FAD is the more complex and abundant form of flavin and is reported to bind to 75% of the total flavoproteome and 84% of human encoded flavoproteins. Cellular concentrations of free or non-covalently bound flavins in a variety of cultured mammalian cell lines were reported for FAD (2.2-17.0 amol/cell) and FMN (0.46-3.4 amol/cell). FAD has a more positive reduction potential than NAD+ and is a very strong oxidizing agent. The cell utilizes this in many energetically difficult oxidation reactions such as dehydrogenation of a C-C bond to an alkene.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.